Instrument Inactif

Communiqués Bone Biologics Corporation Other OTC

Actions

BBLG

US0980702049

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion	20/06	BU
Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th	17/06	AQ
Bone Biologics Announces Closing of $2.0 Million Public Offering	06/03	BU
Bone Biologics Announces Pricing of $2.0 Million Public Offering	04/03	BU
Bone Biologics Reports Progress With NB1 Clinical Program	01/03	BU
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors	11/01	BU
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements	10/01	BU
Bone Biologics Announces 1-for-8 Reverse Stock Split	18/12	BU
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	20/11	BU
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	16/11	BU
Nano-Cap Medical Technology Watchlist (ORHB, BBLG, ICU, RMTI)	02/10/23	AQ
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device	26/09/23	BU
Bone Biologics : Submission of Matters to a Vote of Security Holders - Form 8-K	13/09/23	PU
Bone Biologics Prices $5.0 Million Underwritten Public Offering	15/06/23	BU
Bone Biologics Effects 1-for-30 Reverse Stock Split	06/06/23	BU
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia	11/04/23	BU
BONE BIOLOGICS CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	30/03/23	AQ
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization	26/01/23	BU
BONE BIOLOGICS CORP : Change in Directors or Principal Officers (form 8-K)	21/12/22	AQ
BONE BIOLOGICS CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	21/11/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bone Biologics Corporation Other OTC

Actions

BBLG

US0980702049

Communiqués

Filtres